{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T03:21:50Z","timestamp":1767842510406,"version":"3.49.0"},"reference-count":41,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2009,5,3]],"date-time":"2009-05-03T00:00:00Z","timestamp":1241308800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Acad Dermatol Venereol"],"published-print":{"date-parts":[[2009,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p><jats:bold>Background\u2002<\/jats:bold> Quadrivalent human papillomavirus (HPV types 6\/11\/16\/18) L1 VLP vaccine is highly effective in preventing HPV 6\/11\/16\/18\u2010related cervical and external genital disease. Herein, we evaluated the impact of the quadrivalent HPV 6\/11\/16\/18\u00a0L1 VLP vaccine on prevention of HPV\u2010associated cervico\u2010genital lesions in a broad population of sexually active European women.<\/jats:p><jats:p><jats:bold>Methods\u2002<\/jats:bold> Female subjects (<jats:italic>N<\/jats:italic> = 9265) aged 16\u201324 with four or fewer lifetime sexual partners were enrolled and randomized to quadrivalent HPV vaccine or placebo. Subjects underwent cervicovaginal sampling for HPV DNA detection. Papanicolaou testing and anti\u2010HPV 6\/11\/16\/18 serology testing was also performed.<\/jats:p><jats:p><jats:bold>Results\u2002<\/jats:bold> Vaccine efficacy against lesions representing immediate cervical cancer precursors (cervical intraepithelial neoplasia grade 2\/3 or adenocarcinoma <jats:italic>in situ<\/jats:italic>) related to HPV 6\/11\/16\/18 in the per\u2010protocol population was 100.0%[95% confidence interval (95% CI), 89.8\u2013100.0]. Efficacy against external genital lesions (vulvar or vaginal intraepithelial neoplasia, condyloma, vulvar or vaginal cancer) related to vaccine HPV types in the per\u2010protocol European population was 99.0% (95% CI, 94.4\u2013100.0).<\/jats:p><jats:p><jats:bold>Conclusion\u2002<\/jats:bold> These data demonstrate that quadrivalent HPV 6\/11\/16\/18 vaccination programs in 16\u2010 to 24\u2010year\u2010old European women can be beneficial.<\/jats:p><jats:p>NCT0009252, NCT00092534, NCT00092495<\/jats:p>","DOI":"10.1111\/j.1468-3083.2009.03266.x","type":"journal-article","created":{"date-parts":[[2009,5,4]],"date-time":"2009-05-04T04:03:08Z","timestamp":1241409788000},"page":"1147-1155","source":"Crossref","is-referenced-by-count":25,"title":["The impact of a quadrivalent human papillomavirus (types 6, 11, 16, 18) virus\u2010like particle vaccine in European women aged 16 to 24"],"prefix":"10.1111","volume":"23","author":[{"given":"S","family":"Majewski","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"FX","family":"Bosch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Dillner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"O\u2010E","family":"Iversen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"SK","family":"Kjaer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N","family":"Mu\u00f1oz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S\u2010E","family":"Olsson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J","family":"Paavonen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K","family":"Sigurdsson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J","family":"Bryan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"MT","family":"Esser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K","family":"Giacoletti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"James","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F","family":"Taddeo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S","family":"Vuocolo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E","family":"Barr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2009,9,10]]},"reference":[{"key":"e_1_2_7_2_2","unstructured":"American Cancer Society.Cancer facts and figures.2006.http:\/\/www.cancer.org\/downloads\/STT\/CAFF2006PWSecured.pdf."},{"key":"e_1_2_7_3_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1096-9896(199909)189:1<12::AID-PATH431>3.0.CO;2-F"},{"key":"e_1_2_7_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0029-7844(98)00245-2"},{"key":"e_1_2_7_5_2","doi-asserted-by":"publisher","DOI":"10.1517\/14728214.10.1.5"},{"key":"e_1_2_7_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2006.05.031"},{"key":"e_1_2_7_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(07)70158-5"},{"key":"e_1_2_7_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)67069-9"},{"key":"e_1_2_7_9_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6601024"},{"key":"e_1_2_7_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2006.05.026"},{"key":"e_1_2_7_11_2","doi-asserted-by":"publisher","DOI":"10.1086\/522863"},{"key":"e_1_2_7_12_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa061760"},{"key":"e_1_2_7_13_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa061741"},{"key":"e_1_2_7_14_2","doi-asserted-by":"publisher","DOI":"10.1086\/522864"},{"key":"e_1_2_7_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(05)70101-7"},{"key":"e_1_2_7_16_2","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2006-0461"},{"key":"e_1_2_7_17_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.287.16.2114"},{"key":"e_1_2_7_18_2","first-page":"108","article-title":"Simultaneous quantitation of antibodies to neutralizing epitopes on virus\u2010like particles for human papillomavirus types 6, 11, 16 and 18 by a multiplexed luminex assay","volume":"10","author":"Opalka D","year":"2003","journal-title":"Clin Diagn Lab Immunol"},{"key":"e_1_2_7_19_2","doi-asserted-by":"publisher","DOI":"10.1086\/521679"},{"key":"e_1_2_7_20_2","doi-asserted-by":"crossref","unstructured":"KjaerSK BreugelmansG MunkC.Population\u2010based prevalence type\u2010 and age\u2010specific distribution of HPV in women before introduction of HPV\u2010vaccination program in Denmark.Int J Cancer2008.","DOI":"10.1002\/ijc.23712"},{"key":"e_1_2_7_21_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.325.7364.572"},{"key":"e_1_2_7_22_2","doi-asserted-by":"publisher","DOI":"10.1080\/00365540500333566"},{"key":"e_1_2_7_23_2","first-page":"1459","article-title":"High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6","volume":"95","author":"Villa LL","year":"2006","journal-title":"\/11\/16\/18"},{"key":"e_1_2_7_24_2","doi-asserted-by":"crossref","unstructured":"OlssonS\u2010E VillaLL CostaRet\u00a0al.Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6\/11\/16\/18 L1 virus\u2010like\u2010particle vaccine.Vaccine2007;25:4931\u20134939.","DOI":"10.1016\/j.vaccine.2007.03.049"},{"key":"e_1_2_7_25_2","unstructured":"FerlayJ BrayF PisaniP ParkinDM.GLOBOCAN 2002: cancer incidence mortality and prevalence worldwide. IARC Cancer Base no. 5 Version 2.0 IARC Press. Available at: Www\u2010Depdb.Iarc.Fr\/Globocan\/GLOBOCAN2002.HTM. Accessed March 15 2005: web site 2005."},{"key":"e_1_2_7_26_2","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.22527"},{"key":"e_1_2_7_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajog.2004.01.042"},{"key":"e_1_2_7_28_2","doi-asserted-by":"publisher","DOI":"10.1158\/1055-9965.EPI-04-0812"},{"key":"e_1_2_7_29_2","first-page":"606","article-title":"Cancer incidence in 5 continents","volume":"8","author":"Parkin DM","year":"2002","journal-title":"IRAC Scientific Publication 155, International Abency for Research on Cancer, Lyon, France"},{"key":"e_1_2_7_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2006.05.115"},{"key":"e_1_2_7_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2006.05.111"},{"key":"e_1_2_7_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bpobgyn.2005.10.007"},{"key":"e_1_2_7_33_2","doi-asserted-by":"publisher","DOI":"10.1006\/gyno.2001.6401"},{"key":"e_1_2_7_34_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.AOG.0000245786.86267.80"},{"key":"e_1_2_7_35_2","doi-asserted-by":"publisher","DOI":"10.1006\/gyno.2001.6502"},{"key":"e_1_2_7_36_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19950615)75:12<2879::AID-CNCR2820751214>3.0.CO;2-W"},{"key":"e_1_2_7_37_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.pas.0000213291.96401.48"},{"key":"e_1_2_7_38_2","first-page":"1934","article-title":"Human papillomavirus 16 and 18 L1 serology compared across anogenital cancer sites","volume":"61","author":"Carter JJ","year":"2001","journal-title":"Cancer Res"},{"key":"e_1_2_7_39_2","doi-asserted-by":"publisher","DOI":"10.1006\/gyno.1995.1046"},{"key":"e_1_2_7_40_2","first-page":"393","article-title":"Vulval intraepithelial neoplasia: current perspectives","volume":"22","author":"Jones RW","year":"2001","journal-title":"Eur J Gynaecol Oncol"},{"key":"e_1_2_7_41_2","unstructured":"The UK Collaborative Group for HIV and STI Surveillance.HIV and other Sexually Transmitted Infections in the United Kingdom: 2007. Section 2.5. Genital Human Papillomavirus.Health Protection Agency London 2007."},{"key":"e_1_2_7_42_2","first-page":"598","article-title":"Management of anogenital warts (condylomata acuminata)","volume":"11","author":"Von Krogh G.","year":"2001","journal-title":"Eur J Dermatol"}],"container-title":["Journal of the European Academy of Dermatology and Venereology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1468-3083.2009.03266.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1468-3083.2009.03266.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,11]],"date-time":"2023-10-11T20:41:56Z","timestamp":1697056916000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1468-3083.2009.03266.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,9,10]]},"references-count":41,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2009,10]]}},"alternative-id":["10.1111\/j.1468-3083.2009.03266.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1468-3083.2009.03266.x","archive":["Portico"],"relation":{},"ISSN":["0926-9959","1468-3083"],"issn-type":[{"value":"0926-9959","type":"print"},{"value":"1468-3083","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,9,10]]}}}